382 results about "Ovarian cancer cells" patented technology

TADG-12 and CA125 are two proteins expressed with high specificity in ovarian cancer tumors. They thus would be potential antigens for immunotherapy in ovarian cancer. The invention is based on the discovery of peptides in TADG-12 and CA125 that can be used to induce an autologous T cell response that lyses ovarian cancer cells expressing TADG-12 or CA125. The peptides are contacted with dendritic cells in vitro to generate peptide-loaded dendritic cells. The peptide-loaded dendritic cells are contacted with T cells in vitro to amplify CD8+ T cells that recognize the peptide. At least one CA125 peptide and at least one TADG-12 peptide were found that amplified CD8+ T cells, even from cancer patients, that lysed autologous CA125-expressing or TADG-12-expressing tumor cells. The peptide-loaded dendritic cells can be administered to a cancer patient to amplify CD8+ T cells in vivo that attack the cancer cells. Alternatively, autologous CD8+ T cells can be amplified ex vivo and then infused into the cancer patient.

The invention belongs to the field of traditional Chinese medicine and relates to a traditional Chinese medicine compound preparation for treating ovarian cancer and a preparation method of the traditional Chinese medicine compound preparation. According to the traditional Chinese medicine compound preparation, extracts of bulk medicine such as astragalus mongholicus, codonopsis pilosula, rehmannia root, sculellaria barbata, asparagus cochinchinensis, medlar, cornu cervi, fiveleaf akebia fruit, elecampane and radix paeoniae alba are prepared into solid and liquid preparations. Animal experiment results show that the weight loss and the white cell reduction can be relieved, the T lymphocyte function is improved, the bax expression is increased, the cancer cell apoptosis is promoted, the anti-tumor angiogenesis effect is realized, the oxygen deficiency microenvironment of tumor cells is improved, and the sensitivity of ovarian cancer cells on chemotherapeutics is enhanced. Clinical test results show that the clinical symptoms of later-stage ovarian cancer patients can be relieved, and the survival quality of patients is improved; the chemotherapy toxic and side effect is lightened, and the chemotherapy tolerance and the compliance of the patients are improved; and the uncontrolled and recurrence rate of later-stage ovarian cancer can be reduced, and the five-year survival rate is improved; and no obvious adverse reaction exists, and good safety is realized. The traditional Chinese medicine compound preparation is applicable to the treatment on ovarian cancer and ovarian cancer postoperative chemotherapy patients.

TADG-12 and CA125 are two proteins expressed with high specificity in ovarian cancer tumors. They thus would be potential antigens for immunotherapy in ovarian cancer. The invention is based on the discovery of peptides in TADG-12 and CA125 that can be used to induce an autologous T cell response that lyses ovarian cancer cells expressing TADG-12 or CA125. The peptides are contacted with dendritic cells in vitro to generate peptide-loaded dendritic cells. The peptide-loaded dendritic cells are contacted with T cells in vitro to amplify CD8+ T cells that recognize the peptide. At least one CA125 peptide and at least one TADG-12 peptide were found that amplified CD8+ T cells, even from cancer patients, that lysed autologous CA125-expressing or TADG-12-expressing tumor cells. The peptide-loaded dendritic cells can be administered to a cancer patient to amplify CD8+ T cells in vivo that attack the cancer cells. Alternatively, autologous CD8+ T cells can be amplified ex vivo and then infused into the cancer patient.

The invention discloses an anti-CA125 carbohydrate antigen nano-antibody. The nano-antibody has three unique complementarity determining regions CDR1, CDR2 and CDR3. The invention also discloses an application of the nano-antibody in the preparation of tumor treatment drug and tumor diagnosis reagents. The anti-CA125 nano-body has highly specific recognizing and binding ability to the CA125, has aremarkable ADCC effect on ovarian cancer cells, and can accurately image tumors in mouse bodies.

The invention discloses a method for studying the function and mechanism of an m6A reader YTHDF1 in ovarian cancer. The method comprises the following steps of studying the genetic variation and expression change of an m6A modification related gene in ovarian cancer to determine that the m6A reader YTHDF1 is a main study object; carrying out further studying on the function of YTHDF1 in ovarian cancer cells and mouse models; screening and determining a target gene of the YTHDF1 by comprehensively applying a plurality of high-throughput analysis methods; and carrying out further exploration onthe clinical application feasibility of taking the YTHDF1 as the ovarian cancer molecular target. The invention provides a theoretical basis for clarifying the relationship between m6A and ovarian cancer and defining the carcinogenic function of YTHDF1, and possibly provides a new effective target for clinical diagnosis and treatment of ovarian cancer.

The invention provides a novel antineoplastic drug shown in a molecular formula (I). The synthesis method of the drug is simple and convenient, and the drug can be quickly and efficiently synthesized through microwave-assisted one-pot four-component reaction. The synthesis method comprises the following specific steps: dissolving 2 mmol of p-hydroxybenzaldehyde, 2 mmol of 4-fluoroacetophenone or 4-chloropropiophenone and 2 mmol of malononitrile in 1,4-dioxane; then adding 4 mmol of ammonium acetate; performing microwave (300W)-assisted heating to 120 DEG C, and reacting for 20 minutes; and adding ice water into the reaction mixture to precipitate a product, and then recrystallizing to obtain the product, namely 2-amino-3-cyano pyridine. The compound obtained by the invention is a novel antineoplastic drug shown in the molecular formula (I), and has the activity of obviously inhibiting the proliferation of liver cancer, stomach cancer, mammary cancer, pancreatic cancer, brain cancer, lung cancer and ovarian cancer cells.